Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00712400
Other study ID # OPHT-070703
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2005
Est. completion date January 2010

Study information

Verified date June 2018
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Latanoprost is a synthetic prodrug of 17-phenyl-substituted prostaglandin F2α analog. Used at a dose of one drop per day, it has been reported to produce a 30 to 35% reduction in intraocular pressure. Its mechanism of activation involves augmentation of the eye's natural uveoscleral outflow capacity .

There is evidence that ocular blood flow plays a role in the clinical course of glaucoma. Glaucoma medication that lowers IOP simultaneously increases ocular blood perfusion pressure, which in turn may increase ocular blood flow.

This could well contribute to the partially contradicting results concerning ocular hemodynamic effects of latanoprost. In vitro studies indicate that latanoprost has no effect on ocular vascular tone in therapeutical doses. By contrast, it has been reported in several studies that latanoprost 0.005% increases pulsatile ocular blood flow in patients with primary open angle glaucoma and normal tension glaucoma. This increase in pulsatile ocular blood flow mainly reflects an increase in the choroidal circulation.

Little is known about the potential effect of latanoprost on choroidal blood flow regulation in humans. The present study therefore tries to elucidate whether treatment with latanoprost may alter choroidal blood flow regulation during artificial changes in ocular perfusion pressure. In addition, the present study aims to clarify whether the change in choroidal blood flow after latanoprost administration are due to direct vasoactive effects or due to the increase in ocular perfusion pressure. The second alternative may have important implications on our understanding of glaucoma treatment, because reduction of IOP may then per se result in normalization of ocular blood flow regulation.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date January 2010
Est. primary completion date September 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 35 Years
Eligibility Inclusion Criteria:

- Men aged between 19 and 35 years, nonsmokers

- Body mass index between 15th and 85th percentile (Must et al. 1991)

- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

- Normal ophthalmic findings, ametropia < 3 dpt.

Exclusion Criteria:

- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study

- Treatment in the previous 3 weeks with any drug

- Symptoms of a clinically relevant illness in the 3 weeks before the first study day

- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs

- Blood donation during the previous 3 weeks

- Ametropia >= 3 dpt

- Iris bicolor

Study Design


Intervention

Drug:
Latanoprost 0.005%, Xalatan®
Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Placebo
Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days

Locations

Country Name City State
Austria Department of Clinical Pharmacology Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Choroidal pressure-flow relationship in total 4 hours
See also
  Status Clinical Trial Phase
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT03016234 - IOP Changes With Different Anesthetic Agents During Laparoscopic Colorectal Surgery N/A
Completed NCT04863209 - Effect of Osteopathic Techiniques on Intraocular Pressure N/A
Completed NCT03139708 - The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients Phase 1
Completed NCT02646033 - Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position
Recruiting NCT02697825 - Intraocular Pressure Versus Optic Nerve Sheath Diameter N/A
Completed NCT02985567 - An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children N/A
Withdrawn NCT00837226 - Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP) N/A
Completed NCT02136589 - Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes Phase 4
Completed NCT03123614 - Loteprednol vs. Prednisolone and Fluorometholone Phase 4
Completed NCT05763056 - Effects of Intubation on Intra-ocular Pressure and Optic Nerve Sheath Diameter N/A
Completed NCT03359200 - Analysis of the Microbiota in Goldmann Applanation Tonometers at a Reference Service in Goiânia N/A
Completed NCT02816905 - Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery Phase 4
Withdrawn NCT02558309 - Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure N/A
Completed NCT01786954 - iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery N/A
Completed NCT00552019 - Intraocular Pressure (IOP) Assessed by Dynamic Contour Tonometer (DCT) and Goldman Applanation Tonometry (GAT) N/A
Completed NCT00428740 - Long-Term IOP Fluctuation and VF Progression After Triple Procedure N/A
Completed NCT04360369 - Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry N/A
Completed NCT04521140 - Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Phase 4
Completed NCT05167773 - Clinical Study of the Topcon Tonometer TRK-3